Portal de Periódicos da CAPES

The Duration of Protection from Azithromycin Against Malaria, Acute Respiratory, Gastrointestinal, and Skin Infections When Given Alongside Seasonal Malaria Chemoprevention: Secondary Analyses of Data from a Clinical Trial in Houndé, Burkina Faso, and Bougouni, Mali

2021; Oxford University Press; Volume: 73; Issue: 7 Linguagem: Inglês

10.1093/cid/ciaa1905

1537-6591

Mphatso D. Phiri, Matthew Cairns, Issaka Zongo, Frédéric Nikièma, Modibo Diarra, Rakiswendé Serge Yerbanga, Amadou Barry, Amadou Tapily, Samba Coumaré, Ismaila Théra, Irene Kuepfer, Paul Milligan, Halidou Tinto, Alassane Dicko, Jean‐Bosco Ouédraogo, Brian Greenwood, Daniel Chandramohan, Issaka Sagara,

Influenza Virus Research Studies

Mass drug administration (MDA) with azithromycin (AZ) is being considered as a strategy to promote child survival in sub-Saharan Africa, but the mechanism by which AZ reduces mortality is unclear. To better understand the nature and extent of protection provided by AZ, we explored the profile of protection by time since administration, using data from a household-randomized, placebo-controlled trial in Burkina Faso and Mali.